L

Liquidia Corp
D

LQDA

16.110
USD
-0.39
(-2.36%)
مغلق
حجم التداول
31,898
الربح لكل سهم
-2
العائد الربحي
-
P/E
-10
حجم السوق
1,363,495,964
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABEO
    -0.04000
    (-0.69%)
    5.78000 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    SNY
    SNY
    0.325
    (0.60%)
    54.445 USD
    المزيد
الأخبار
المقالات

العنوان: Liquidia Corp

القطاع: Healthcare
الصناعة: Biotechnology
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.